For the roughly 1 in every 200 adults in Western countries living with Crohn's disease, the search for a treatment that keeps symptoms at bay for the long haul is a constant challenge. The condition, a form of inflammatory bowel disease (IBD), can cause debilitating abdominal pain, diarrhea, fatigue, and weight loss, often cycling through periods of flare-ups and remission. While several biologics have entered the market over the past two decades, many patients still cycle through therapies as their disease outsmarts each drug. That is why new long-term data from Johnson & Johnson on its drug Tremfya (guselkumab) is drawing attention. The company reported that adults with moderately to severely active Crohn's disease who took Tremfya achieved sustained clinical and endoscopic remission through three years, a milestone that suggests the drug could offer durable relief where other options fall short.
What the Three-Year Data Show
The findings come from an extension study of the Phase 3 GALAXI program, which evaluated Tremfya in patients who had an inadequate response or were intolerant to conventional therapies, including corticosteroids, immunomodulators, and anti-TNF biologics. After three years of treatment, a significant proportion of patients remained in clinical remission, meaning their Crohn's Disease Activity Index (CDAI) score dropped below 150, and in endoscopic remission, meaning their intestinal lining showed no signs of active inflammation. These results build on earlier one- and two-year data that already hinted at Tremfya's staying power. For a chronic condition like Crohn's, where the goal is to prevent long-term complications such as strictures and fistulas, the ability to maintain remission over multiple years is a big deal.
Dr. Maria Abreu, a gastroenterologist at the University of Miami and a lead investigator in the GALAXI trials, noted in a statement that the three-year data "reinforce the potential of guselkumab as a long-term treatment option" for patients who have failed other therapies. While the exact percentages of patients in remission were not disclosed in the initial announcement, the consistency of the response across both clinical and endoscopic measures is noteworthy. Endoscopic remission, in particular, is a stricter endpoint that correlates with better long-term outcomes, including reduced need for surgery and hospitalization.
Why This Matters for Patients and Physicians
Crohn's disease is notoriously unpredictable. A drug that works well for one patient may lose effectiveness within months for another, and even those who respond initially often see their symptoms return as the body develops antibodies against the medication. This has led to a treatment paradigm where patients and doctors are constantly weighing the risks and benefits of switching therapies. A drug like Tremfya, which targets the p19 subunit of interleukin-23 (IL-23), works differently from anti-TNF drugs like Humira and Remicade. By blocking a specific inflammatory pathway, it may offer a more targeted approach with fewer off-target effects. The three-year data suggest that this mechanism translates into durable remission for a meaningful subset of patients.
For patients, the implication is clear: there may soon be another option that not only induces remission but also helps maintain it over the long term. That could mean fewer flares, less time on steroids, and a lower likelihood of surgery. For physicians, the data provide reassurance that Tremfya can be considered as a first-line biologic or as a switch option for those who have failed other treatments. The safety profile also appears consistent with earlier studies, with no new safety signals emerging over the three-year period.
The Competitive Landscape in IBD
Tremfya is not the only IL-23 inhibitor in the spotlight. AbbVie's Skyrizi (risankizumab) and Eli Lilly's Omvoh (mirikizumab) are also targeting the same pathway, and both have shown promising results in Crohn's and ulcerative colitis. This has created a fierce rivalry in the IBD space, with companies racing to capture a share of a market that is expected to exceed $10 billion by 2030. Johnson & Johnson, which already markets Stelara (ustekinumab), another IL-12/23 inhibitor, sees Tremfya as a successor that could eventually replace Stelara as its flagship IBD drug. Stelara is set to lose patent protection in the coming years, so establishing Tremfya's long-term efficacy is crucial for J&J to retain its dominance.
Analysts have projected that Tremfya could achieve peak sales of $5 billion or more across all indications, which include psoriasis, psoriatic arthritis, and ulcerative colitis in addition to Crohn's. The three-year Crohn's data, if it holds up in the full dataset, would strengthen that forecast. It also positions J&J to compete more effectively with AbbVie, which has been aggressive in promoting Skyrizi. In clinical trials, Skyrizi has shown high rates of endoscopic remission at one year, but long-term data beyond two years are still maturing. Tremfya's three-year showing gives J&J a potential edge in the durability conversation.
What to Watch Next
The full results from the three-year analysis are expected to be presented at a major medical congress later this year, likely the United European Gastroenterology Week or the American College of Gastroenterology annual meeting. That presentation will include detailed remission rates, safety data, and subgroup analyses that could reveal which patients benefit most. Meanwhile, J&J is also studying Tremfya in ulcerative colitis, with Phase 3 results anticipated in the near future. If positive, those data could further expand the drug's label and solidify its place in the IBD treatment algorithm.
For now, the three-year Crohn's data offer a ray of hope. Crohn's disease is a lifelong condition that can be physically and emotionally draining, and having a treatment that can keep it under control for years is a significant step forward. As the IBD market becomes more crowded, the winners will be those that can demonstrate not just short-term efficacy but also long-term durability. Tremfya's latest data suggest it is well-positioned to be one of them.
Frequently Asked Questions
What is Tremfya and how does it work?
Tremfya (guselkumab) is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), a cytokine involved in inflammatory pathways. By blocking IL-23, it helps reduce inflammation in the gut and other tissues. It is administered as an injection and is approved for plaque psoriasis and psoriatic arthritis, with Crohn's disease and ulcerative colitis in development.
What does sustained remission mean in Crohn's disease?
Sustained remission means that a patient's symptoms remain controlled over a long period, typically assessed by clinical scores like the Crohn's Disease Activity Index (CDAI) and endoscopic evaluation. Clinical remission generally means a CDAI score below 150, while endoscopic remission means no visible ulcers or inflammation in the intestine. Sustained remission over three years indicates the treatment is providing durable benefit.
How does Tremfya compare to other biologics for Crohn's?
Tremfya belongs to the IL-23 inhibitor class, which also includes Skyrizi (risankizumab) and Omvoh (mirikizumab). These drugs are generally considered to have a more targeted mechanism than anti-TNF agents like Humira, potentially offering better safety profiles. Head-to-head trials are lacking, but Tremfya's three-year data suggest it is among the most durable options. The choice of therapy depends on patient history, disease severity, and prior treatments.
Is Tremfya approved for Crohn's disease?
As of now, Tremfya is not approved for Crohn's disease. It is approved for moderate-to-severe plaque psoriasis and active psoriatic arthritis. Johnson & Johnson has submitted regulatory applications for Crohn's disease and ulcerative colitis based on Phase 3 data, and approvals are pending in the U.S. and Europe. The three-year data will support those applications and potential label expansions.